Getinge reported strong Q4 19 numbers – beating ours as well as consensus estimates. Growth was driven by Acute Care Therapies and Life Science, which offset the weakness in Surgical Workflows. Regionally, the softness in APAC was partly offset by strong performance in the Americas. Adjusted EBIT came in at SEK1.55bn (margin at 18.2%) and proposed dividend of SEK 1.5/share. Looking ahead, management expects 2-4% organic growth in FY 20. Following the strong numbers, we will be upgrading
01 Feb 2020
Acute care leads a good finish to 2019.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Acute care leads a good finish to 2019.
Getinge AB Class B (GTN:FRA) | 0 0 0.9% | Mkt Cap: 25,911m
- Published:
01 Feb 2020 -
Author:
Virendra Chauhan -
Pages:
3
Getinge reported strong Q4 19 numbers – beating ours as well as consensus estimates. Growth was driven by Acute Care Therapies and Life Science, which offset the weakness in Surgical Workflows. Regionally, the softness in APAC was partly offset by strong performance in the Americas. Adjusted EBIT came in at SEK1.55bn (margin at 18.2%) and proposed dividend of SEK 1.5/share. Looking ahead, management expects 2-4% organic growth in FY 20. Following the strong numbers, we will be upgrading